Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma
Open Access
- 24 October 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (24) , 9581-9594
Abstract
Lung adenocarcinoma (LUAD) is the most common and lethal cancer worldwide. Radiotherapy (RT) is widely used at all stages of LUAD, and the development of immunotherapy substantially enhances the survival of LUAD patients. Although the emerging treatments for LUAD have improved prognosis, only a small fraction of patients can benefit from clinical therapies. Thereby, approaches assessing responses to RT and immunotherapy in LUAD patients are essential. After integrating the analysis of RT, immunization, mRNA, and clinical information, we constructed a signature based on 308 tumor‐infiltrating B lymphocyte‐specific genes (TILBSig) using a machine learning method. TILBSig was composed of 6 B cell‐specific genes (PARP15, BIRC3, RUBCNL, SP110, TLE1, and FADS3), which were highly associated with the overall survival as independent factors. TILBSig was able to differentiate better survival compared with worse survival among different patients, and served as an independent factor for clinical characteristics. The low‐risk TILBSig group was correlated with more immune cell infiltration (especially B lineages) and lower cancer stem cell characteristics than the high‐risk group. The patients with lower risk scores were more likely to respond to RT and immunotherapy. TILBSig served as an excellent predicator for prognosis and response to immunotherapy and RT in LUAD patients.Keywords
Funding Information
- National Natural Science Foundation of China (81773236, 81800429, 81972852)
This publication has 69 references indexed in Scilit:
- CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian CancerClinical Cancer Research, 2012
- Tunicamycin sensitizes human prostate cells to TRAIL-induced apoptosis by upregulation of TRAIL receptors and downregulation of cIAP2International Journal of Oncology, 2012
- Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activityGut, 2011
- cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18–Infected Lung CancerClinical Cancer Research, 2010
- cIAP2 as a therapeutic target in colorectal cancer and other malignanciesExpert Opinion on Therapeutic Targets, 2009
- MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), Amplified on Chromosome 9, Collaborate with p53 Deficiency in Mouse Osteosarcoma ProgressionCancer Research, 2009
- Exploring the role of cancer stem cells in radioresistanceNature Reviews Cancer, 2008
- Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiationRadiotherapy and Oncology, 2007
- Targeting Molecular Determinants of Tumor Chemo-RadioresistanceSeminars in Oncology, 2005
- From Mice to HumansCancer Research, 2004